Idiopathic Inflammatory Myopathies: Current and Future Therapeutic Options

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 548-557

  Wiendl, Heinz ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

dermatomyositis; Idiopathic inflammatory myopathies; inclusion body myositis; myositis; polymyositis; therapy

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXANDROLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; B LYMPHOCYTE; CELL MIGRATION; CLINICAL TRIAL; DERMATOMYOSITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; EDEMA; HEMOLYTIC ANEMIA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; LONG TERM CARE; LOW DRUG DOSE; MEDICAL RESEARCH; NEPHROTOXICITY; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DERMATOMYOSITIS; HUMANS; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 53049091129     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.008     Document Type: Article

References (71)

1. Engel A.G., Hohlfeld R., and Banker B.Q. The polymyositis and dermatomyositis syndromes. In: Engel A.G., and Franzini-Armstrong C. (Eds). Myology. 2nd ed. (1994), Mc Graw Hill, New York 1335-1383
2. Dalakas M.C., and Hohlfeld R. Polymyositis and dermatomyositis. Lancet 362 9388 (2003) 971-982
3. Goebels N., and Pongratz D. Myositiden. In: Brandt Th., Dichgans J., and Diener H.C. (Eds). Therapie und Verlauf neurologischer Erkrankungen. 4th ed. (2003), Kohlhammer Verlag, Stuttgart 1284-1299 (Hrsg)
4. Amato A.A., and Griggs R.C. Treatment of inflammatory myopathies. Curr Opin Neurol 16 (2003) 569-575
5. Hengstman G.J., and van Engelen B.G. Polymyositis: an overdiagnosed entity. Neurology 63 (2004) 402-403
6. Wiendl H., Hohlfeld R., and Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 26 (2005) 373-380 a
7. Dalakas M.C. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2 (2006) 398 a
8. Hohlfeld R., and Dornmair K. Revisiting the immunopathogenesis of the inflammatory myopathies. Neurology 69 (2007) 1966-1967
9. Chevrel G., Goebels N., and Hohlfeld R. Myositis: Diagnosis and management. Pract Neurol 1 (2002) 4-11
10. Hohlfeld R. Polymyositis and Dermatomyositis. In: Karpati G. (Ed). Structural and molecular basis of skeletal muscle disease (2002), ISN Neuropath Press, Basel 221-227
11. Wiendl H., Hohlfeld R., and Kieseier B.C. Muscle-derived positive and negative regulators of the immune response. Curr Opin Rheumatol 17 (2005) 714-719
12. Suber T.L., Casciola-Rosen L., and Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 4 (2008) 201-209
13. Needham M., and Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6 (2007) 620-631
14. Dalakas M.C. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2 (2006) 437-447
15. Askanas V., and Engel W.K. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19 (2007) 550-559
16. Airio A., Kautiainen H., and Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25 (2006) 231-239
17. Marie I., Hachulla E., Hatron P.Y., Hellot M.F., Levesque H., Devulder B., and Courtois H. Polymyositis and dematomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28 (2002) 2230-2237
18. Choy E.H., and Isenberg D.A. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 41 (2002) 7-13
19. Miller F.W., Rider L.G., Chung Y.L., et al., International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40 (2001) 1262-1273
20. Isenberg D.A., Allen E., Farewell V., et al., International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43 (2004) 49-54
21. Bunch T.W. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum 24 (1981) 5-48
22. Riley S.A., Williams S.E., and Cooke N.J. Alveolitis after treatment with amiodarone. Br Med J (Clin Res Ed) 284 6310 (1982) 161-162
23. Schnabel A., Hellmich B., and Gross W.L. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep 7 (2005) 99-105
24. Fossaluzza V., and De Vita S. Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome. Clin Rheumatol 11 (1992) 385-387
25. Majithia V., and Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44 (2005) 386-389
26. Choudry V., Cornblath D.R., Griffin J.W., O'Brien R., and Drachman D.B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56 (2001) 94-96
27. Schneider-Gold C., Hartung H.P., and Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34 (2006) 284-291
28. Vernino S., Salomao D.R., Habermann T.M., and O'Neill B.P. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 65 (2005) 639-641
29. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C., Dinsmore S.T., and McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329 (1994) 1993-2000
30. Stringer E., and Feldman B.M. Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 18 (2006) 503-506
31. Cherin P., Pelletier S., Teixeira A., Laforet P., Genereau T., Simon A., Maisonobe T., Eymard B., and Herson S. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheumat 46 (2002) 467-474
32. Dalakas M.C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291 (2004) 2367-2375
33. Mastaglia F.L., and Zilko P.J. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 10 (2003) 99-101
34. Sekul E.A., Chow C., and Dalakas M.C. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 48 (1997) 863-866
35. Dalakas M.C., Koffman B., Fujii M., et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56 (2001) 323-327
36. Lindberg C., Trysberg E., Tarkowski A., and Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61 (2003) 260-262
37. Nakayama T., Horiuchi E., Watanabe T., Murayama S., and Nakase H. A case of inclusion body myositis with benign monoclonal gammopathy successfully responding to repeated immunoabsorption. J Neurol Neurosurg Psychiatry 68 (2000) 230-233
38. Rutkove S.B., Parker R.A., Nardin R.A., Connolly C.E., Felice K.J., and Raynor E.M. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 58 (2002) 1081-1087
39. Dalakas M.C., Rakocevic G., McElroy B., Salajegheh M., Love M.H., Shrader J., Levy E., and Kirk A.D. Alemtuzumab (CAMPATH 1-H) therapy in sporadic inclusion body myositis (sIBM): a treatment trial in patients with established natural history data. AAN 2007, S57.001. Neurology 12 168 (2007) A361
40. Dalakas M.C., Sonies B., Dambrosia J., Sekul E., Cupler E., and Sivakumar K. Treatment of inclusion-body myositis with IVIG: a double-blind, placebo-controlled study. Neurology 48 (1997) 712-716
41. Walter M.C., Lochmüller H., Toepfer M., et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 247 (2000) 22-28
42. Pisoni C.N., Cuadrado M.J., Khamashta M.A., Hughes G.R., and D'Cruz D.P. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 46 (2007) 516-518
43. Rowin J., Amato A.A., Deisher N., Cursio J., and Meriggioli M.N. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 66 (2006) 1245-1247
44. Barohn R.J., Herbelin L., Kissel J.T., King W., McVey A.L., Saperstein D.S., and Mendell J.R. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66 suppl 1 (2006) S123-S124
45. Wilkes M.R., Sereika S.M., Fertig N., Lucas M.R., and Oddis C.V. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52 (2005) 2439-2446
46. Takada K., Nagasaka K., and Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38 (2005) 383-392
47. Ochi S., Nanki T., Takada K., Suzuki F., Komano Y., Kubota T., and Miyasaka N. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 23 (2005) 707-710
48. Greenberg S.A. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 69 (2007) 2008-2019
49. Cooper M.A., Willingham D.L., Brown D.E., et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56 (2007) 3107-3111
50. Chung L., Genovese M.C., and Fiorentino D.F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143 (2007) 763-767
51. Dinh H.V., McCormack C., Hall S., et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 56 (2007) 148-153
52. Ferrer E., and Moral M.A. Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura. Drug News Perspect 19 (2006) 482-484
53. Brulhart L., Waldburger J.M., and Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65 (2006) 974-975
54. Chiappetta N., Steier J., and Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 11 (2005) 264-266
55. Lambotte O., Kotb R., Maigne G., Blanc F.X., Goujard C., and Delfraissy J.F. Efficacy of rituximab in refractory polymyositis. J Rheumatol 32 (2005) 1369-1370
56. Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52 (2005) 601-607
57. Noss E.H., Hausner-Sypek D.L., and Weinblatt M.E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33 (2006) 1021-1026
58. Mok C.C., Ho L.Y., and To C.H. Rituximab for refractory polymyositis: an open-label pilot study. Ann Rheum Dis 66 suppl II (2007) 216
59. Lebwohl M., Tyring S.K., Hamilton T.K., et al. Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
60. Cooper J.C., Morgan G., Harding S., Subramanyam M., Majeau G.R., Moulder K., and Alexander D.R. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 33 (2003) 666-675
61. Bluestone J.A., St Clair E.W., and Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24 (2006) 233-238
62. Vugmeyster Y., Kikuchi T., Lowes M.A., et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113 (2004) 38-46
63. Lowes M.A., Chamian F., Abello M.V., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 102 (2005) 19057-19062
64. Leonardi C.L. Efalizumab: an overview. J Am Acad Dermatol 49 2 suppl (2003) S98-S104
65. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., Barohn R.J., Saperstein D.S., Briemberg H.R., Ericsson M., Park P., and Amato A.A. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57 (2005) 664-678
66. Schmidt K.N., and Ouyang W. Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. Lupus 13 (2004) 348-352
67. Stewart T.A. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14 (2003) 139-154
68. Dzionek A., Sohma Y., Nagafune J., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194 (2001) 1823-1834
69. Patole P.S., Zecher D., Pawar R.D., Gröne H.J., Schlöndorff D., and Anders H.J. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16 (2005) 3273-3280
70. Zozulya A.L., and Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 4 (2008) 384-398
71. Greenberg S.A., Sanoudou D., Haslett J.N., Kohane I.S., Kunkel L.M., Beggs A.H., and Amato A.A. Molecular profiles of inflammatory myopathies. Neurology 59 8 (2002) 1170-1182